BioLargo

US: BLGO

$27.9m market cap

$0.16 last close

BioLargo has a number of subsidiaries and products focused on using iodine chemistry. CupriDyne is a product that is currently on the market for industrial odor control. The subsidiary Clyra Medical is a wound care company with an iodine-based irrigation solution and ClyraGuard, a disinfectant for healthcare workers. It is developing the AOS as a low-cost water purification device. Finally, the company has a full service environmental engineering team.

Investment summary

Clyra Medical, BioLargo’s partially owned (36%) subsidiary, recently announced that it registered with the FDA and launched Clyraguard, a disinfectant marketed for the treatment of non-critical surfaces such as personal protective equipment (PPE) that is non-irritating to skin. Concurrent with this BioLargo announced the results of two studies that showed Clyraguard and the company’s environmental product CupriDyne could both fully inactivate COVID-19.

Sector
Healthcare
Share price graph
Price performance
%
1m
3m
12m
Actual 9.9 (26.2) (13.9)
Relative* 0.4 (25.8) (22.4)
52-week high/low US$0.4/US$0.1
*% relative to local index
Key management
Dennis Calvert President & CEO